RET and hypertensive disorder: Selpercatinib and Pralsetinib are more selective RET inhibitors with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes, however, they both inhibit to a lesser degree VEGFR, PDGFR, and FGFR, and therefore they can also give rise to a lesser degree hypertension, hemorrhagic events, impaired wound healing, hepatotoxicity, and interstitial lung disease/pneumonitis.